EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

RANKL-derived peptide MHP1-AcN attenuates ovariectomy-induced osteoporosis by targeting RANK and TNFR1 in mice

Takuya Kurihara, Munehisa Shimamura, Yuki Etani, Takaaki Noguchi, Yuji Fukuda, Nagahiro Ochiai, Atsushi Goshima, Taihei Miura, Makoto Hirao, Atsushi Sugimoto, Nan Ju, Satoshi Yamakawa und 4 weitere

Bone · 2025

DOI: 10.1016/j.bone.2025.117440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bone, 2025. Verfasst von Takuya Kurihara und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Ovariectomy, Osteoporosis, RANK Ligand, Receptors, Tumor Necrosis Factor, Type I. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Co Ltd, Asahi Kasei Pharma Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Estrogen deficiency following menopause increases receptor activator of nuclear factor-kappa B ligand (RANKL) expression in osteoblasts, thereby promoting osteoclast differentiation, and enhances T cell-derived tumor necrosis factor-alpha (TNFα) production, which induces sclerostin expression in osteocytes, thereby inhibiting bone formation. This study aimed to develop a novel uncoupling therapeutic agent for osteoporosis. METHODS: We developed microglial healing peptide 1 with N-terminal acetylation and C-terminal amidation (MHP1-AcN), a modified RANKL peptide with N-terminal acetylation and C-terminal amidation lacking the osteoclast activating CD loop. Given the structural similarities of RANK and TNF receptor 1 (TNFR1), we hypothesized that MHP1-AcN could inhibit both the RANKL-RANK and TNFα-TNFR1 pathways to address the pathophysiology of osteoporosis, as evaluated in vitro and in vivo using an ovariectomized mouse model. RESULTS: In ovariectomized mice, MHP1-AcN inhibited osteoclastogenesis, reduced osteocytic sclerostin expression, prevented bone loss, and improved the femoral cancellous and cortical bone microarchitecture. Unlike anti-RANKL antibody, MHP1-AcN considerably preserved bone formation by osteoblasts and enhanced bone strength, as evidenced by increases in energy absorption capacity. In vitro, MHP1-AcN bound to both RANK and TNFR1, suppressing osteoclast activity via the RANKL-RANK pathway and reducing sclerostin expression through the TNFα-TNFR1-nuclear factor-kappa B pathway. MHP1-AcN did not affect osteoblast proliferation and differentiation or RANKL expression. CONCLUSION: MHP1-AcN effectively inhibits osteoclastogenesis and sclerostin-mediated suppression of bone formation while considerably preserving osteoblast function. These findings suggest that MHP1-AcN, which targets dual pathways critical for bone homeostasis, is a promising uncoupling therapeutic agent for osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OvariectomyOsteoporosisRANK LigandReceptors, Tumor Necrosis Factor, Type IPeptidesReceptor Activator of Nuclear Factor-kappa BAnimalsFemaleMiceOsteogenesisMice, Inbred C57BLOsteoclastsOsteoblastsAdaptor Proteins, Signal TransducingCell DifferentiationTumor Necrosis Factor-alphaSignal TransductionOsteocytes

Stichwörter der Autor:innen

Microglial healing peptide 1 with N-terminal acetylation and C-terminal amidati…OsteoblastOsteoclastOsteocytePostmenopausal osteoporosisRANKL

Substanzen

RANK LigandReceptors, Tumor Necrosis Factor, Type IPeptidesReceptor Activator of Nuclear Factor-kappa BAdaptor Proteins, Signal TransducingTumor Necrosis Factor-alpha

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Department of Gene & Stem Cell Regenerative Therapy, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan; Department of Sports Medical Biomechanics, Osaka University Graduate School of Medicine, 2-2…
  • Department of Musculoskeletal Regenerative Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan.
  • Department of Orthopaedic Surgery, Osaka Rosai Hospital, 1179-3 Nagasonecho, Kita-ku, Sakai, Osaka 591-8025, Japan.
  • Clinical and Research Institute for Foot and Ankle Surgery, Jujo Hospital, 341-1 Mangoku, Kisarazu, Chiba 292-0003, Japan.

Förderung

  • Eisai Co Ltd
  • Asahi Kasei Pharma Corporation

Zitieren

APA

Kurihara, T., Shimamura, M., Etani, Y., Noguchi, T., Fukuda, Y., Ochiai, N., Goshima, A., Miura, T., Hirao, M., Sugimoto, A., Ju, N., Yamakawa, S., Kanamoto, T., Nakata, K., Okada, S., & Ebina, K. (2025). RANKL-derived peptide MHP1-AcN attenuates ovariectomy-induced osteoporosis by targeting RANK and TNFR1 in mice. Bone. https://doi.org/10.1016/j.bone.2025.117440

Vancouver

Kurihara T, Shimamura M, Etani Y, Noguchi T, Fukuda Y, Ochiai N, et al. RANKL-derived peptide MHP1-AcN attenuates ovariectomy-induced osteoporosis by targeting RANK and TNFR1 in mice. Bone. 2025. doi:10.1016/j.bone.2025.117440

BibTeX
@article{Kurihara2025,
  author = {Kurihara, Takuya and Shimamura, Munehisa and Etani, Yuki and Noguchi, Takaaki and Fukuda, Yuji and Ochiai, Nagahiro and Goshima, Atsushi and Miura, Taihei and Hirao, Makoto and Sugimoto, Atsushi and Ju, Nan and Yamakawa, Satoshi and Kanamoto, Takashi and Nakata, Ken and Okada, Seiji and Ebina, Kosuke},
  title = {RANKL-derived peptide MHP1-AcN attenuates ovariectomy-induced osteoporosis by targeting RANK and TNFR1 in mice},
  journal = {Bone},
  year = {2025},
  doi = {10.1016/j.bone.2025.117440}
}
Kostenlos starten →